TB-HAART trial--authors' reply
Lancet Infect Dis
.
2015 Jan;15(1):15-6.
doi: 10.1016/S1473-3099(14)71051-5.
Authors
Sayoki G Mfinanga
1
,
Bruce J Kirenga
2
,
Duncan M Chanda
3
,
Cathy Connolly
4
,
Peter Mwaba
5
,
Moses Joloba
6
,
Alimuddin Zumla
7
;
TB-HAART Study Group
Affiliations
1
National Institute for Medical Research (NIMR), Muhumbili Centre, Tanzania.
2
Department of Medicine, Makerere University College of Health Sciences, Mulago Hospital, Kampala, Uganda.
3
Institute for Medical Research & Training (IMReT), University Teaching Hospital, Lusaka, Zambia. Electronic address: duncan.chanda@gmail.com.
4
Clinical Trials Unit, Medical Research Council, Durban, South Africa.
5
Institute for Medical Research & Training (IMReT), University Teaching Hospital, Lusaka, Zambia.
6
Supra-National TB Laboratory, Ministry of Health, Kampala, Uganda.
7
University College London, and NIHR Biomedical research centre, University College Hospitals, London, United Kingdom.
PMID:
25541163
DOI:
10.1016/S1473-3099(14)71051-5
No abstract available
Publication types
Letter
Comment
MeSH terms
Anti-HIV Agents / administration & dosage*
Antiretroviral Therapy, Highly Active / methods*
Female
HIV Infections / drug therapy*
Humans
Male
Tuberculosis, Pulmonary / drug therapy*
Substances
Anti-HIV Agents